Some newer medications (like tirzepatide ) target both GLP-1 and GIP receptors , which may improve both blood sugar control and weight loss results
Pros: Superior weight loss results, multireceptor approach Cons: Phase II clinical trials, awaiting FDA approval Semaglutide FDA-approved for weight loss, semaglutide offers up to 15%-20% weight loss
From a dosing frequency perspective, all three medications share the convenience of once-weekly subcutaneous injection, making them broadly comparable in terms of administration burden
Each patch can be worn for up to 8 hours
Microneedle patches are an active area of research
Lupus, Sjgrens, and Ankylosing Spondylitis and More GLP-1s may calm immune responses, offset steroid-induced weight gain, protect the kidneys, and lower heart disease risk